Dr. Kimberly L. Blackwell on a Promising HER2 Breast Cancer Treatment

Kimberly L. Blackwell, MD, professor of Medicine, assistant professor of Radiation Oncology, Duke Cancer Institute, discusses upcoming trials for the HER2-antibody margetuximab.

Kimberly L. Blackwell, MD, professor of Medicine, assistant professor of Radiation Oncology, Duke Cancer Institute, discusses upcoming trials for the HER2-antibody margetuximab. She says the drug was initially tested in both phase I and II trials, though the trials are being repeated to test margetuximab’s effectiveness on HER2-positive breast cancer.

Blackwell also says that if approved, margetuximab could benefit patients with HER2 over-expression that are not eligible for trastuzumab.